LEO Pharma Announces Changes to Executive Leadership
29.1.2025 14:00:00 CET | LEO Pharma | Pressemeddelelse
null
Ballerup, 29 January 2025 – Today, LEO Pharma announces the appointment of a new Executive Vice President, North America. Robert Spurr will join the Global Leadership Team and serve as CEO and President, LEO Pharma Inc. United States. Robert succeeds Brian Hilberdink, who will be leaving LEO Pharma to pursue an external opportunity in a large pharmaceutical company.
Robert joined LEO Pharma in 2023 as Vice President of Market Access, Patient Services, Sales, and Health Economics and Outcomes Research (HEOR) and a member of the North America Leadership Team. Prior to LEO Pharma, he previously held numerous senior leadership positions at Novartis, Johnson and Johnson, and Repligen. Robert also served as President of Bausch Healthcare Companies Inc.
“I am thrilled to step into the role of EVP of Region North America and CEO & President of LEO Pharma Inc. US,” said Robert Spurr “As LEO Pharma undergoes significant transformation with a clear strategy for the future, I am eager to leverage my experience to drive our continued success. With a strong growth trajectory and a dedicated team, I am confident we can deliver great results.”
Robert Spurr will officially step into the EVP role on January 29, 2025. Brian Hilberdink’s last day at LEO Pharma will be on February 11, 2025.
“During my tenure at LEO Pharma, I have witnessed the incredible drive and passion across Region North America. I’m proud to have had the opportunity to lead and help propel the Region into a significant growth trajectory,” said Brian Hilberdink, former EVP of Region North America and CEO & President of LEO Pharma Inc. US. “It has not been an easy decision to leave LEO Pharma, and I have every confidence in the future success of the organization.”
“I would like to thank Brian for his key contribution in accelerating LEO Pharma’s growth trajectory in North America and for building a strong team,” said LEO Pharma CEO, Christophe Bourdon. “Robert’s track record and leadership qualities make him ideally suited to his new role. Over the last 18 months I have been truly impressed by his key contributions to the US affiliate. I would like to congratulate him on his appointment and welcome him as a member of LEO Pharma’s Global Leadership Team. His contributions will be instrumental in further strengthening our growth trajectory in North America.”
Kontakter
Jeppe Ilkjær
LEO Pharma, Global Communications
Tel: +45 30 50 20 14
Email: JEILK@leo-pharma.com
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care through innovation for the benefit of people with skin conditions. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. LEO Pharma offers a broad portfolio of treatments, serving 100 million patients annually. Headquartered in Denmark, LEO Pharma has a global team of 4,000 people. In 2023, the company generated net sales of DKK 11.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma elects Henriette Mersebach to the Board of Directors14.8.2026 09:00:00 CEST | Pressemeddelelse
Henriette Mersebach will bring deep pharmaceutical R&D and innovation expertise to the Board
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis9.7.2026 17:00:00 CEST | Pressemeddelelse
TRAPEDS-1 is a Phase 2 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.1 The pharmacokinetic profile was as expected and consistent with what has previously been observed with tralokinumab. Tralokinumab was generally well tolerated for up to 172 weeks of treatment, with no new safety signals identified.
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen25.6.2026 13:00:00 CEST | Pressemeddelelse
New data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1 Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2
LEO Pharma’s net-zero and emissions reduction targets validated by SBTi8.6.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma has achieved Science Based Targets initiative (SBTi) validation for its net-zero climate targets, including its ambition to reach net-zero greenhouse gas emissions by 2050, alongside near-term goals to reduce Scope 1 and 2 emissions by 63% and Scope 3 emissions by 37.5% by 2035 With its targets now validated, LEO Pharma is shifting from target-setting to implementation, advancing 15 prioritized initiatives in its Climate Transition Plan while emphasizing the connection between environmental health and patient care
LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i Danmark7.5.2026 09:00:00 CEST | Pressemeddelelse
LOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum